The National Cancer Institute (NCI) is offering this R33 grant to support the advanced development and rigorous validation of emerging molecular and cellular analysis technologies. This grant is for novel technologies that can target, probe, or assess cancer biology, aiming to accelerate research in areas like early detection, diagnosis, treatment, and addressing health disparities. Applicants should demonstrate that major feasibility gaps for their technology have been overcome, but further development is required for broader adoption. This NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program seeks projects focused on improving molecular and/or cellular characterizations of cancer, not applications of existing technologies.
Opportunity ID: 357738
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-25-002 |
| Funding Opportunity Title: | Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | 10 |
| Assistance Listings: | 93.394 — Cancer Detection and Diagnosis Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Dec 16, 2024 |
| Last Updated Date: | Dec 16, 2024 |
| Original Closing Date for Applications: | Oct 03, 2025 |
| Current Closing Date for Applications: | Oct 03, 2025 |
| Archive Date: | Nov 08, 2025 |
| Estimated Total Program Funding: | $300,000 |
| Award Ceiling: | $300,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | For profit organizations other than small businesses State governments Native American tribal governments (Federally recognized) City or township governments Others (see text field entitled “Additional Information on Eligibility” for clarification) County governments Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Independent school districts Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-002.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 357738 Full Announcement-RFA-CA-25-002 -> RFA-CA-25-002-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-I | Use for due dates on or after January 25, 2025 | PKG00289682 | Mar 04, 2025 | Oct 03, 2025 | View |
Package 1
Mandatory forms
357738 RR_SF424_5_0-5.0.pdf
357738 PHS398_CoverPageSupplement_5_0-5.0.pdf
357738 RR_OtherProjectInfo_1_4-1.4.pdf
357738 PerformanceSite_4_0-4.0.pdf
357738 RR_KeyPersonExpanded_4_0-4.0.pdf
357738 RR_Budget_3_0-3.0.pdf
357738 PHS398_ResearchPlan_5_0-5.0.pdf
357738 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
357738 RR_SubawardBudget30_3_0-3.0.pdf
357738 PHS_AssignmentRequestForm_4_0-4.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
